As part of the prospective-retrospective validation in clinical trial cohorts, it was shown that EP could identify more patients as low risk compared with classical pathological parameters and can help to reduce chemotherapy in low risk ER pos, HER2 neg breast cancer patients [3–7]. This evidence concerns the gene ERBB2 and breast carcinoma.